ICAM1 and neoplasm: Given the critical role of ICAM-1 in CD8+ T cells, we hypothesized that high ICAM-1 expression in CD8+ T cells could augment the systemic antitumor effect of RT, and therefore conducted RT in combination with ACT in mice with more advanced (approximately 200 mm3) distant tumors in the bilateral MC38 tumor-bearing WT C57BL/6 mice model.